Browsing Tag
Bristol Myers Squibb
44 posts
Bristol Myers Squibb Gains U.S. FDA Approval to Remove REMS Programs and Ease Monitoring Rules for Breyanzi and Abecma Cell Therapies
Bristol Myers Squibb gains U.S. FDA approval to remove REMS and reduce monitoring for Breyanzi and Abecma cell therapies, expanding access for blood cancer patients.
Checkpoint inhibitors in early-stage cancer: A new era of adjuvant therapy is taking shape
Checkpoint inhibitors are redefining early-stage cancer care. Find out how Tecentriq, Keytruda, and others are competing for the adjuvant immunotherapy market.
Biotech layoffs 2025: Prothena joins the wave—What’s driving the restructuring trend?
Explore why Prothena’s layoffs reflect a growing 2025 biotech downsizing trend. What’s causing the wave, and who might be next?
Why Alzheimer’s partnerships with Roche, BMS, and Novo Nordisk still matter for Prothena
Explore how Prothena’s strategic collaborations with Roche, BMS, and Novo Nordisk could shape the future of Alzheimer’s drug development.
Prothena halts birtamimab development after Phase 3 AFFIRM-AL trial fails to meet endpoints
Prothena ends birtamimab development after failed Phase 3 trial in AL amyloidosis. Find out how this impacts its pipeline, financials, and future direction.
Bristol Myers Squibb’s Opdualag fails to meet primary endpoint in Phase 3 trial
Bristol Myers Squibb has announced that its Phase 3 RELATIVITY-098 clinical trial, designed to evaluate Opdualag (nivolumab and…
FDA approves Opdivo Qvantig, a new subcutaneous immunotherapy option for cancer treatment
In a significant advancement for oncology care, the U.S. Food and Drug Administration (FDA) has approved Opdivo Qvantig…
Schrödinger stock skyrockets as Novartis invests billions in new partnership
In a landmark development, Schrödinger, Inc. has entered into a multi-target research collaboration and expanded software licensing agreement…
AbbVie’s schizophrenia treatment crumbles, boosting Bristol Myers Squibb to the top
Bristol Myers Squibb’s stock surged dramatically after pharmaceutical giant AbbVie announced disappointing results in its recent clinical trials…
Study results spark 13% drop in Perspective Therapeutics shares – Radiation levels in focus
Shares of Perspective Therapeutics (NYSE AMERICAN: CATX) fell sharply, dropping over 13% to $11.49, after the latest data…